DK0623352T3 - Biofunktionelle glycoproteiner med et modificeret carbonhydrat-komplement og deres anvendelse ved tumorselektiv terapi - Google Patents
Biofunktionelle glycoproteiner med et modificeret carbonhydrat-komplement og deres anvendelse ved tumorselektiv terapiInfo
- Publication number
- DK0623352T3 DK0623352T3 DK94106394T DK94106394T DK0623352T3 DK 0623352 T3 DK0623352 T3 DK 0623352T3 DK 94106394 T DK94106394 T DK 94106394T DK 94106394 T DK94106394 T DK 94106394T DK 0623352 T3 DK0623352 T3 DK 0623352T3
- Authority
- DK
- Denmark
- Prior art keywords
- glycoproteins
- tumor
- carbohydrate complement
- biofunctional
- complement
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 150000001720 carbohydrates Chemical class 0.000 title abstract 5
- 102000003886 Glycoproteins Human genes 0.000 title abstract 4
- 108090000288 Glycoproteins Proteins 0.000 title abstract 4
- 230000000295 complement effect Effects 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 230000001588 bifunctional effect Effects 0.000 abstract 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 abstract 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 abstract 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Chemical group CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 abstract 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 abstract 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Chemical group CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 229930182830 galactose Chemical group 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 abstract 1
- 229950006780 n-acetylglucosamine Drugs 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4314556A DE4314556A1 (de) | 1993-05-04 | 1993-05-04 | Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0623352T3 true DK0623352T3 (da) | 2002-11-11 |
Family
ID=6487030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94106394T DK0623352T3 (da) | 1993-05-04 | 1994-04-25 | Biofunktionelle glycoproteiner med et modificeret carbonhydrat-komplement og deres anvendelse ved tumorselektiv terapi |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8552159B2 (da) |
| EP (1) | EP0623352B1 (da) |
| JP (1) | JPH06319554A (da) |
| KR (1) | KR100387452B1 (da) |
| AT (1) | ATE220921T1 (da) |
| AU (1) | AU684750B2 (da) |
| CA (1) | CA2122745C (da) |
| DE (2) | DE4314556A1 (da) |
| DK (1) | DK0623352T3 (da) |
| ES (1) | ES2177554T3 (da) |
| PT (1) | PT623352E (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19513676A1 (de) | 1995-04-11 | 1996-10-17 | Behringwerke Ag | Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli |
| SI0795334T1 (sl) * | 1996-03-12 | 2006-06-30 | Sanofi Aventis Deutschland | Predzdravila za zdravljenje tumorjev in vnetnih bolezni |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
| US7691810B2 (en) | 2003-10-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Method of producing recombinant antithrombin III composition |
| KR101540319B1 (ko) | 2013-10-01 | 2015-07-30 | 한국생명공학연구원 | cyb5R3 유전자 또는 단백질을 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물 |
| MX2020006822A (es) * | 2018-01-04 | 2020-09-03 | Shanghai Lumosa Therapeutics Co Ltd | Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4859449A (en) * | 1987-09-14 | 1989-08-22 | Center For Molecular Medicine And Immunology | Modified antibodies for enhanced hepatocyte clearance |
| US5632990A (en) * | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
| GB8809616D0 (en) * | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
| US5135736A (en) * | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| GB8905669D0 (en) * | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| DE4106389A1 (de) * | 1991-02-28 | 1992-09-03 | Behringwerke Ag | Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung |
| GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| AU656181B2 (en) * | 1991-05-03 | 1995-01-27 | Pasteur Sanofi Diagnostics | Heterobifunctional antibodies possessing dual catalytic and specific antigen binding properties and methods using them |
| DE4233152A1 (de) * | 1992-10-02 | 1994-04-07 | Behringwerke Ag | Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung |
-
1993
- 1993-05-04 DE DE4314556A patent/DE4314556A1/de not_active Withdrawn
-
1994
- 1994-04-25 DK DK94106394T patent/DK0623352T3/da active
- 1994-04-25 DE DE69431018T patent/DE69431018T2/de not_active Expired - Lifetime
- 1994-04-25 EP EP94106394A patent/EP0623352B1/en not_active Expired - Lifetime
- 1994-04-25 PT PT94106394T patent/PT623352E/pt unknown
- 1994-04-25 AT AT94106394T patent/ATE220921T1/de active
- 1994-04-25 ES ES94106394T patent/ES2177554T3/es not_active Expired - Lifetime
- 1994-05-02 AU AU61829/94A patent/AU684750B2/en not_active Expired
- 1994-05-03 CA CA2122745A patent/CA2122745C/en not_active Expired - Lifetime
- 1994-05-04 KR KR1019940009786A patent/KR100387452B1/ko not_active IP Right Cessation
- 1994-05-06 JP JP6117524A patent/JPH06319554A/ja active Pending
-
2004
- 2004-04-02 US US10/815,925 patent/US8552159B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0623352A3 (en) | 1995-02-22 |
| AU6182994A (en) | 1994-11-10 |
| PT623352E (pt) | 2002-12-31 |
| DE69431018T2 (de) | 2003-02-27 |
| DE69431018D1 (de) | 2002-08-29 |
| US20040202646A1 (en) | 2004-10-14 |
| JPH06319554A (ja) | 1994-11-22 |
| CA2122745A1 (en) | 1994-11-05 |
| DE4314556A1 (de) | 1994-11-10 |
| US8552159B2 (en) | 2013-10-08 |
| EP0623352A2 (en) | 1994-11-09 |
| EP0623352B1 (en) | 2002-07-24 |
| CA2122745C (en) | 2010-06-22 |
| ES2177554T3 (es) | 2002-12-16 |
| AU684750B2 (en) | 1998-01-08 |
| ATE220921T1 (de) | 2002-08-15 |
| KR100387452B1 (ko) | 2003-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1245320A1 (zh) | 治療缺陷α半乳糖苷酶A的藥物製劑 | |
| DK0490077T3 (da) | Antisense-oligonukleotider til behandling af cancer | |
| TR200002243T2 (tr) | Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı. | |
| IL88428A0 (en) | Anti-tumor drug-monoclonal antibody conjugates | |
| BRPI9809791B8 (pt) | compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos | |
| IL130931A0 (en) | Small molecules useful in the treatment of inflammatory disease | |
| NL191308C (nl) | Gelyofiliseerd, na oplossing injecteerbaar preparaat dat een antracycline-glycoside bevat, alsmede werkwijze voor de bereiding van een injecteerbare oplossing van een antracycline-glycoside. | |
| ATE197903T1 (de) | Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken | |
| EE200000039A (et) | MHC II klassi ligandi kasutamine, farmatseutiline kompositsioon, transfekteeritud kasvajarakud, transfekteeritud rakkude ja kasvajarakkude valmistamismeetod ning nende kasutamine | |
| DE68912334T2 (de) | Immunokonjugate für krebs-diagnose und -therapie. | |
| DK0623352T3 (da) | Biofunktionelle glycoproteiner med et modificeret carbonhydrat-komplement og deres anvendelse ved tumorselektiv terapi | |
| HUP9801746A2 (hu) | Limfotoxin-alfa/béta komplexek és anti-limfotoxin-béta receptor antitestek mint tumorellenes szerek | |
| IL116511A0 (en) | Mutant enzymes | |
| EP0524931A1 (en) | METHOD FOR SENSITIZING TUMOR CELLS. | |
| DE69821498D1 (de) | Verwendung von amifostin | |
| NO880908L (no) | Kombinasjonsterapi med bruk av antitumor immunotoksiner med tumornekrosefaktor. | |
| DE69630727D1 (de) | Radioaktiven Chitosankomplex und deren Anwendung in Strahlungstherapie | |
| DK0512002T3 (da) | ||
| ES2119738T3 (es) | Profarmacos de etoposido de glicosilo, procedimiento para su preparacion y su aplicacion en combinacion con conjugados enzimaticos funcionalizados, especificos de tumores. | |
| NZ240926A (en) | Radioactively labelled modified oligonucleotide labelled with a therapeutic isotope and compositions thereof | |
| NO995109L (no) | Formuleringer inneholdende 1,2,4-benzotriazinoksyder | |
| ATE235888T1 (de) | Lyophilisiertes thioxanthenon-antitumormedikament | |
| WO1996012508A3 (en) | Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy | |
| TR200000728T2 (tr) | Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı. | |
| TWI265811B (en) | Extended type 1 chain glycosphingolipids as tumor-associated antigens |